<SEC-DOCUMENT>0001193125-20-191424.txt : 20200713
<SEC-HEADER>0001193125-20-191424.hdr.sgml : 20200713
<ACCEPTANCE-DATETIME>20200713060512
ACCESSION NUMBER:		0001193125-20-191424
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200713
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200713
DATE AS OF CHANGE:		20200713

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Equillium, Inc.
		CENTRAL INDEX KEY:			0001746466
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				821554746
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38692
		FILM NUMBER:		201024241

	BUSINESS ADDRESS:	
		STREET 1:		2223 AVENIDA DE LA PLAYA
		STREET 2:		SUITE 105
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
		BUSINESS PHONE:		(858) 412-5302

	MAIL ADDRESS:	
		STREET 1:		2223 AVENIDA DE LA PLAYA
		STREET 2:		SUITE 105
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d39771d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of report (date of earliest event reported): July&nbsp;13, 2020 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>EQUILLIUM, INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-38692</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">82-1554746</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>2223 Avenida de la Playa, Suite 105, La Jolla, CA</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>92037</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: (858)
<FONT STYLE="white-space:nowrap">412-5302</FONT> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17
CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">14d-2(b)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">13e-4(c)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&nbsp;12(b) of the Act: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title of each class</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Trading</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Symbol(s)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name of each exchange</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>on which registered</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">Common Stock, par value $0.0001 per share</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">EQ</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">The Nasdaq Global Market</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (&#167; 230.405 of this chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 (&#167; <FONT STYLE="white-space:nowrap">240.12b-2</FONT> of this chapter). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&#9746; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange
Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;8.01 Other Events. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;13, 2020, Equillium, Inc. (the &#147;<B>Company</B>&#148;) announced that a clinical trial conducted by its partner, Biocon
Limited, demonstrated that itolizumab significantly reduced mortality in patients hospitalized with <FONT STYLE="white-space:nowrap">COVID-19</FONT> in India and that the Drugs Controller General of India, the regulatory agency that oversees drug
approvals in India, has granted restricted emergency use of itolizumab for the treatment of cytokine release syndrome in <FONT STYLE="white-space:nowrap">COVID-19</FONT> patients with moderate to severe acute respiratory distress syndrome in India.
The Company, which has the right to develop and commercialize itolizumab in the U.S., Canada, Australia and New Zealand, is planning to conduct a global randomized, controlled clinical trial of itolizumab in
<FONT STYLE="white-space:nowrap">COVID-19</FONT> patients for which it will file a U.S. investigational new drug application. A copy of the press release discussing these matters is filed as Exhibit 99.01, and incorporated by reference in, this
report. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01 Financial Statements and Exhibits. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="91%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" NOWRAP>(d)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description.</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">99.01</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d39771dex991.htm">Press release, dated July&nbsp;13, 2020, issued by Equillium, Inc. </A></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>EQUILLIUM, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Date: July&nbsp;13, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Bruce D. Steel</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Bruce D. Steel</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">President and Chief Executive Officer</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d39771dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.01 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g39771g0713085759574.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Clinical Trial Shows Itolizumab Reduces Mortality in Patients Hospitalized with <FONT
STYLE="white-space:nowrap">COVID-19</FONT> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Equillium shares topline results of patients treated with itolizumab in clinical
trial conducted in India by partner Biocon </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Biocon has received emergency use approval from Drugs Controller General of India
for itolizumab in the treatment of CRS in <FONT STYLE="white-space:nowrap">COVID-19</FONT> patients with moderate to severe ARDS </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Equillium planning global randomized controlled clinical trial of itolizumab in <FONT STYLE="white-space:nowrap">COVID-19</FONT> patients
under a U.S. IND </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>LA JOLLA, Calif., July</B><B></B><B>&nbsp;13, 2020 &#150; </B>Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology
company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that as reported by its partner, <U>Biocon Limited</U>, a clinical trial conducted in India by Biocon demonstrated that itolizumab significantly
reduced mortality in patients hospitalized with <FONT STYLE="white-space:nowrap">COVID-19.</FONT> Biocon has <U>announced</U> that the Drugs Controller General of India (DCGI), the regulatory agency that oversees drug approvals, has granted
restricted emergency use of itolizumab for the treatment of cytokine release syndrome (CRS) in <FONT STYLE="white-space:nowrap">COVID-19</FONT> patients with moderate to severe acute respiratory distress syndrome (ARDS) in India. Based on the
encouraging topline results of the study reported by Biocon and subsequent DCGI approval to treat <FONT STYLE="white-space:nowrap">COVID-19</FONT> patients, Equillium is planning to conduct a global randomized controlled clinical trial of itolizumab
in <FONT STYLE="white-space:nowrap">COVID-19</FONT> patients for which it will file a U.S. investigational new drug application (IND). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Biocon conducted a
randomized, controlled, open-label study at four hospitals in India, enrolling a total of 30 hospitalized <FONT STYLE="white-space:nowrap">COVID-19</FONT> patients with moderate to severe ARDS. Twenty patients were randomized to receive itolizumab
plus best supportive care, while 10 patients received best supportive care alone. The primary endpoint was mortality at one month. As reported by Biocon: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In the itolizumab arm there were no deaths and all patients have recovered; in the control arm three patients
died and the remainder have recovered </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The mortality benefit observed in the itolizumab arm was statistically significant </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Consistent with the observed clinical improvement, patients who received itolizumab also experienced significant
reductions in inflammatory cytokines such as <FONT STYLE="white-space:nowrap">IL-6</FONT> and TNF&#945; </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;The results of this
clinical trial reported by Biocon are encouraging and support the hypothesis that itolizumab&#146;s novel immune-modulating mechanism may have promise in addressing the severe immuno-inflammatory complications experienced by <FONT
STYLE="white-space:nowrap">COVID-19</FONT> patients,&#148; said Bruce Steel, <FONT STYLE="white-space:nowrap">co-founder</FONT> and CEO of Equillium. &#147;We are working with Biocon to review its full dataset with the goal to move swiftly in
determining appropriate next steps to accelerate further development of itolizumab to treat moderate to severely ill <FONT STYLE="white-space:nowrap">COVID-19</FONT> patients in the U.S. and abroad in the face of this global crisis.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;As the entire world grapples with the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic it is critical to identify new treatments that
improve outcomes for the sickest patients, and these reported early clinical data suggest that itolizumab holds promise,&#148; said Siddhartha Mukherjee, M.D., Ph.D., a clinical advisor to Equillium and Biocon, Pulitzer Prize Award-winning author,
and an Associate Professor of Medicine at Columbia University&#146;s Herbert Irving Comprehensive Cancer Center. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ivor S. Douglas, M.D., FRCP (UK) Professor of Medicine, Chief of Pulmonary and Critical Care and Medical
Director, Medical Intensive Care Denver Health Medical Center, added &#147;Patients with <FONT STYLE="white-space:nowrap">COVID-19</FONT> experience acute respiratory failure caused by the immune system flooding the bloodstream with inflammatory
proteins, which can kill tissue, damage organs and pathologically activate clotting cascades in the lungs, heart, and kidneys. The novel mechanism of itolizumab, which works by inhibiting CD6 to reduce the activation and trafficking of pathogenic T
cells that release <FONT STYLE="white-space:nowrap">pro-inflammatory</FONT> cytokines, may be well suited to address <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> induced inflammation that drives
respiratory failure in patients with <FONT STYLE="white-space:nowrap">COVID-19.</FONT> The preliminary data as reported by Biocon is encouraging and highlights the urgent importance of further evaluating the potential therapeutic efficacy of
itolizumab in treating patients diagnosed with <FONT STYLE="white-space:nowrap">COVID-19.&#148;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Itolizumab is a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">first-in-class</FONT></FONT> immune-modulating antibody therapeutic with a novel mechanism of action that inhibits the activity and trafficking of pathogenic T cells that release
<FONT STYLE="white-space:nowrap">pro-inflammatory</FONT> cytokines in a range of autoimmune and inflammatory diseases. Equillium acquired rights to develop and commercialize itolizumab in the U.S., Canada, Australia and New Zealand through an
exclusive collaboration and license agreement with Biocon. Equillium is currently evaluating itolizumab under two open U.S. INDs for the treatment of acute graft-versus-host disease and lupus nephritis, as well as conducting a clinical study in
uncontrolled asthma in Australia and New Zealand. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Biocon previously developed and received approval of Itolizumab for the treatment of plaque psoriasis
in India, demonstrating the product was safe and well tolerated. Biocon manufactures itolizumab at commercial scale at its cGMP <FONT STYLE="white-space:nowrap">bio-manufacturing</FONT> facility that is regulated by the U.S. Food&nbsp;&amp; Drug
Administration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March of this year, as a result of the emerging <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, Equillium announced that it
was pausing enrollment in the EQUIP trial for uncontrolled asthma and the EQUALISE trial for lupus nephritis. Today Equillium announces that patient enrollment in both of these studies has resumed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Equillium </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Equillium is a clinical-stage
biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Equillium&#146;s initial product candidate, itolizumab, is a clinical-stage,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> monoclonal antibody that selectively targets the <FONT STYLE="white-space:nowrap">CD6-ALCAM</FONT> pathway. This pathway plays a central role in
modulating the activity and trafficking of T cells that drive a number of immuno-inflammatory diseases. Itolizumab is a clinically validated therapeutic that has demonstrated a favorable safety and tolerability profile.&nbsp;Equillium acquired
rights to itolizumab through an exclusive partnership with Biocon Limited. Itolizumab is currently marketed in India under the trade name, &#147;ALZUMab&#148; for the treatment of chronic plaque psoriasis and in July 2020 received emergency use
approval in India to treat CRS in <FONT STYLE="white-space:nowrap">COVID-19</FONT> patients with moderate to severe ARDS.&nbsp;Equillium believes that itolizumab has the potential to be a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">best-in-class</FONT></FONT> disease modifying therapeutic and is advancing the clinical development of itolizumab in the following severe immuno-inflammatory disorders: uncontrolled asthma, acute graft-versus-host disease,
and lupus nephritis. For more information, visit&nbsp;<U>www.equilliumbio.com</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Statements contained in this press release regarding matters that are not historical facts are &#147;forward-looking statements&#148; within the meaning of the
Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but
are not limited to, statements regarding the potential </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
benefit of treating <FONT STYLE="white-space:nowrap">COVID-19</FONT> patients with itolizumab, planned clinical studies as a result of data reported by Biocon, Equillium&#146;s business strategy,
Equillium&#146;s plans and expected timing for developing itolizumab, including the expected timing of initiating a clinical trial in patients with <FONT STYLE="white-space:nowrap">COVID-19,</FONT> and the impact of the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic. Risks that contribute to the uncertain nature of the forward-looking statements include uncertainties pending full review by Equillium of the Biocon dataset and uncertainties related to
Equillium&#146;s capital requirements, Equillium&#146;s plans and product development, including the initiation, restarting and completion of clinical trials, including a clinical trial of patients with
<FONT STYLE="white-space:nowrap">COVID-19,</FONT> uncertainties related to the actual impacts and length of such impacts caused by the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, uncertainties caused by the pausing of the EQUIP and
EQUALISE clinical trials, whether the results from clinical trials will validate and support the safety and efficacy of itolizumab, having to use cash in ways or on timing other than expected and the impact of market volatility on cash reserves.
These and other risks and uncertainties are described more fully under the caption &#147;Risk Factors&#148; and elsewhere in Equillium&#146;s filings and reports with the United States Securities and Exchange Commission. All forward-looking
statements contained in this press release speak only as of the date on which they were made. Equillium undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were
made. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Contact </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Christine Zedelmayer, Chief
Operating Officer </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">+1-858-412-5302</FONT></FONT></FONT>
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>ir@equilliumbio.com </U></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Contact </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cammy Duong </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Canale Communications </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">+1-619-849-5389</FONT></FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>cammy@canalecomm.com </U></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g39771g0713085759574.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g39771g0713085759574.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !) + # 2(  A$! Q$!_\0
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M_P #:-7FJ."Z)/[[_P"0\D 9)P!534);D:=+)8&)I]O[LN?EI=3_ .05=_\
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MV!ZU;LO$$>IZH;:Q@>:V13YEST4'L!ZU5\06US9ZA;Z[91F1X%\NXB7J\?\
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9$"(H50,  8 I:*Z:5&%)6@K&D81BM#__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
